By Tony Fong
NEW YORK (GenomeWeb News) – Having demonstrated the utility of its technology, molecular diagnostics firm Sequenta will focus on clinical validation of its technology in 2012 with an expected launch of its first product next year.
Registering provides access to this and other free content.
Already have an account?Login Now.
The New York Times' George Johnson muses on cancer's roots in multicellularity.
The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.
Jun Wang, the chief executive of BGI, has stepped down.
In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.